Business

Part 2: Ryan Cox on Whether Midsize Employers Have a Voice in Biosimilar Discussions

October 8, 2020

Video

Ryan Cox, vice president of the Access Experience Team at PRECISIONvalue, discusses whether midsize employers can participate in payer discussions on formulary placement.

Part 1: Ryan Cox on What Employers Need to Do to Boost Biosimilar Uptake

October 7, 2020

Video

Ryan Cox, vice president of the Access Experience Team at PRECISIONvalue, discusses what employers can do to encourage biosimilar uptake and what cultural changes are needed to make it happen.

IQVIA: Biosimilars Could Save $100 Billion Over Next 5 Years

October 6, 2020

Skylar Jeremias

Article

A report from the IQVIA Institute for Human Data Science states that assessments of the health of the US biosimilar market are too conservative.

EMA Begins Review of Samsung Bioepis' Ranibizumab

October 6, 2020

Tony Hagen

Article

The European Medicines Agency (EMA) regulatory review advances a pact between Samsung Bioepis and Biogen announced last year.

Medicure and Reliance Team Up for Cardiovascular Biosimilar

October 6, 2020

Tony Hagen

Article

The agreement enables Reliance Life Sciences to springboard into the US market using Medicure's commercial reach.

Review: FDA Should Reconsider Interchangeability Requirements

October 5, 2020

Tony Hagen

Article

Researchers contend the "totality of evidence" for biosimilar approval may be sufficient to demonstrate interchangeability.

Accord Launches 2 Biosimilars in the UK, Expands Partnership With Henlius

October 2, 2020

Skylar Jeremias

Article

Accord brought 2 biosimilars referencing blockbuster oncology products to the United Kingdom and amended its agreement with Shanghai Henlius Biotech.

Potential Cost Savings From Improving Biosimilar Availability in Slovakia

October 1, 2020

Deana Ferreri, PhD

Article

Biosimilars could improve health system sustainability in Slovakia; however, of the 54 biosimilars approved by the European Medicines Agency as of August 2019, fewer than half are available in Slovakia

Centus’ Avastin Biosimilar Receives EC Approval

October 1, 2020

Skylar Jeremias

Article

Centus’ Equidacent became Europe’s fourth bevacizumab biosimilar to receive marketing authorization.

Report: Biosimilar Savings Have Grown, but Uptake Barriers Remain

September 30, 2020

Skylar Jeremias

Article

Over the past decade, savings from biosimilars have grown; however, there remain barriers that prevent biosimilar savings from reaching their full potential, according to a report from the Association for Accessible Medicines.

x